C12N 2501/2317
Interleukin-17
Official title: Interleukin-17 (IL-17)
C12N2501/2317 (Interleukin-17) appears on 6 US grants and 28 published applications in this corpus.
Search patents in C12N- Granted patents
- 6
- Published applications
- 28
- Assignees
- 21
- Inventors
- 59
- Latest grant
- 3 Dec 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 0 | 2 |
| 2016 | 0 | 2 |
| 2017 | 0 | 0 |
| 2018 | 1 | 0 |
| 2019 | 1 | 3 |
| 2020 | 0 | 1 |
| 2021 | 1 | 4 |
| 2022 | 0 | 3 |
| 2023 | 1 | 3 |
| 2024 | 2 | 3 |
| 2025 | 0 | 4 |
| 2026 | 0 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of administering mesenchymal stem cells activated by cytokines for enhancing immunosuppression3 Dec 2024US 12,156,889 B2Rutgers, The State University of New Jersey
- Methods for inducing an immune response by administering activated mesenchymal stem cells16 Jan 2024US 11,872,250 B2Rutgers, The State University of New Jersey
- Kit containing medium for culturing natural killer cells and method of effectively culturing natural killer cells using the same31 Jan 2023US 11,566,227 B2Forevernk Inc.
- Methods of producing activated mesenchymal stem cells26 Jan 2021US 10,898,523 B2Rutgers, The State University of New Jersey
- Muscle stem cell in vitro culture method and application14 May 2019US 10,287,549 B2Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
- Method of treating heart failure in subjects with persistent inflammation16 Jul 2026US 2026/0199396 A1Mesoblast International Sarl
- Pre-licensed composition and cell culture methods16 Jul 2026US 2026/0201337 A1Mesoblast International Sarl
- Methods of making chimeric antigen receptor-expressing cells26 Feb 2026US 2026/0055157 A1Novartis AG
- Sirpa deficient macrophages for treating cancer30 Oct 2025US 2025/0333698 A1Georgia State University Research Foundation, Inc.
- Regulatory t cell stability assay14 Aug 2025US 2025/0258162 A1Abata Therapeutics, Inc.
Most cited
By later US patents